LakePharma launches its CHO GSN platform for CHO stable cell line development

Added On: 2015-09-16

LakePharma announced the availability of a new parental cell line produced through a joint effort with Horizon Discovery Group plc (LSE: HZD). 

The gene-engineered Chinese Hamster Ovary (CHO) cell line, adapted to manufacturing conditions by LakePharma, is now offered by LakePharma as a parental cell line in its stable cell line generation platform and available for license and commercial use by clients.

LakePharma adapted Horizon’s CHO cell to suspension growth in commercially available animal component free, chemically defined media, and carried out a full evaluation of protein expression. The decision to partner was based upon a successful evaluation, showing significantly higher antibody titers at the stable pool stage relative to LakePharma’s previous system.